ZATECKY, Jan, Oldřich COUFAL, Ondřej ZAPLETAL, Otakar KUBALA, Marketa KEPICOVA, Adela FARIDOVA, Karel RAUS, Jiri GATEK, Peter KOSAC and Matus PETEJA. Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial. World Journal of Surgical Oncology. London: BioMed Central, 2023, vol. 21, No 1, p. 1-9. ISSN 1477-7819. Available from: https://dx.doi.org/10.1186/s12957-023-03147-x.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Ideal marker for targeted axillary dissection (IMTAD): a prospective multicentre trial
Authors ZATECKY, Jan (203 Czech Republic, guarantor), Oldřich COUFAL (203 Czech Republic), Ondřej ZAPLETAL (203 Czech Republic, belonging to the institution), Otakar KUBALA (203 Czech Republic), Marketa KEPICOVA (203 Czech Republic), Adela FARIDOVA (203 Czech Republic), Karel RAUS (203 Czech Republic), Jiri GATEK (203 Czech Republic), Peter KOSAC (203 Czech Republic) and Matus PETEJA (203 Czech Republic).
Edition World Journal of Surgical Oncology, London, BioMed Central, 2023, 1477-7819.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30212 Surgery
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.200 in 2022
RIV identification code RIV/00216224:14110/23:00133385
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1186/s12957-023-03147-x
UT WoS 001049914600002
Keywords in English Targeted axillary dissection; Breast cancer; Magnetic seed; Iodine seed; Clip; Carbon suspension
Tags 14110813, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 1/2/2024 14:09.
Abstract
BackgroundTargeted axillary dissection (TAD) is an established method for axillary staging in patients with breast cancer after neoadjuvant chemotherapy (NAC). TAD consists of sentinel lymph node biopsy and initially pathological lymph node excision, which must be marked by a reliable marker before NAC.MethodsThe IMTAD study is a prospective multicentre trial comparing three localisation markers for lymph node localisation (clip + iodine seed, magnetic seed, carbon suspension) facilitating subsequent surgical excision in the form of TAD. The primary outcome was to prospectively compare the reliability, accuracy, and safety according to complication rate during marker implantation and detection and marker dislodgement.ResultsOne hundred eighty-nine patients were included in the study-in 135 patients clip + iodine seed was used, in 30 patients magnetic seed and in 24 patients carbon suspension. The complication rate during the marker implantation and detection were not statistically significant between individual markers (p = 0.263; p = 0.117). Marker dislodgement was reported in 4 patients with clip + iodine seed localisation (3.0%), dislodgement did not occur in other localisation methods (p = 0.999). The false-negativity of sentinel lymph node (SLN) was observed in 8 patients, the false-negativity of targeted lymph nodes (TLN) wasn & PRIME;t observed at all, the false-negativity rate (FNR) from the subcohort of ypN + patients for SLN is 9.6% and for TLN 0.0%.ConclusionThe IMTAD study indicated, that clip + iodine seed, magnetic seed and carbon suspension are statistically comparable in terms of complications during marker implantation and detection and marker dislodgement proving their safety, accuracy, and reliability in TAD. The study confirmed, that the FNR of the TLN was lower than the FNR of the SLN proving that the TLN is a better marker for axillary lymph node status after NAC.
PrintDisplayed: 24/8/2024 14:48